

7. American Academy of Pediatrics and American College of Obstetricians and Gynecologists. Inpatient perinatal care services. In: Hauth JC, Merenstein GB, eds. *Guidelines for Perinatal Care*. 4th ed. Elk Grove Village, IL: American Academy of Pediatrics; 1997:13-50.
8. Laboratory Centre for Disease Control. Influenza in Canada: 1997-1998 season. *CCDR* 1998;24:169-176.
9. Dagan R, Hall CB. Influenza A virus infection imitating bacterial sepsis in early infancy. *Pediatr Infect Dis J* 1984;3:218-221.
10. Potter MN, Foot AB, Oakhill A. Influenza A and the virus associated haemophagocytic syndrome: cluster of three cases in children with acute leukaemia. *J Clin Pathol* 1991;44:297-299.
11. Haley RW, Cushion NB, Tenover FC, Bannerman TL, Dryer D, Ross J, et al. Eradication of endemic methicillin-resistant *Staphylococcus aureus* infections from a neonatal intensive care unit. *J Infect Dis* 1995;171:614-624.
12. Haley RW, Bregman DA. The role of understaffing and overcrowding in recurrent outbreaks of staphylococcal infection in a neonatal special-care unit. *J Infect Dis* 1982;145:875-885.
13. Moisiuk SE, Robson D, Klass L, Kliever G, Wasyluk W, Dari M, et al. Outbreak of parainfluenza virus type 3 in an intermediate care neonatal nursery. *Pediatr Infect Dis J* 1998;17:49-53.
14. Valenti WM, Clarke TA, Hall CB, Menegus MA, Shapiro DL. Concurrent outbreaks of rhinovirus and respiratory syncytial virus in an intensive care nursery: epidemiology and associated risk factors. *J Pediatr* 1982;100:722-726.
15. Wilson CW, Stevenson DK, Arvin AM. A concurrent epidemic of respiratory syncytial virus and echovirus 7 infections in an intensive care nursery. *Pediatr Infect Dis J* 1989;8:24-29.
16. Nagels B, Ritter E, Thomas P, Schulte-Wisserman H, Wirsing von Konig CH. *Acinetobacter baumannii* colonization in ventilated preterm infants. *Eur J Clin Microbiol Infect Dis* 1998;17:37-40.
17. Cordero L, Ayers LW, Davis K. Neonatal airway colonization with gram-negative bacilli: association with severity of bronchopulmonary dysplasia. *Pediatr Infect Dis J* 1997;16:18-23.
18. Garcia DC, Trevisan AR, Botto L, Cervetto M, Sarubbi MA, Zorzopulos J. An outbreak of multiply resistant *Pseudomonas aeruginosa* in a neonatal unit: plasmid pattern analysis. *J Hosp Infect* 1989;14:99-105.
19. de Sierra TM, Kumar ML, Wasser TE, Murphy BR, Subbarao EK. Respiratory syncytial virus-specific immunoglobulins in preterm infants. *J Pediatr* 1993;122:787-791.
20. Simoes EAF, King SJ, Lehr MV, Groothuis JR. Preterm twins and triplets: a high-risk group for severe respiratory syncytial virus infection. *Am J Dis Child* 1993;147:303-306.
21. Dominguez EA, Taber LH, Couch RB. Comparison of rapid diagnostic techniques for respiratory syncytial and influenza A virus respiratory infections in young children. *J Clin Microbiol* 1993;31:2286-2290.
22. Hijazi Z, Pacsa A, Eisa S, el Shazli A, abd el-Salam RA. Laboratory diagnosis of acute lower respiratory tract viral infections in children. *J Trop Pediatr* 1996;42:276-280.
23. Wiselka M. Influenza: diagnosis, management, and prophylaxis. *BMJ* 1994;308:1341-1345.
24. Englund JA, Champlin RE, Wyde PR, Kantarjian H, Atmar RL, Tarrand J, et al. Common emergence of amantadine-resistant influenza A viruses in symptomatic immunocompromised adults. *Clin Infect Dis* 1998;26:1418-1424.
25. Klimov AI, Rocha E, Hayden FG, Shult PA, Roumillat LF, Cox NJ. Prolonged shedding of amantadine-resistant influenza A viruses by immunodeficient patients: detection by polymerase chain reaction-restriction analysis. *J Infect Dis* 1995;172:1352-1355.
26. Hayden FG, Osterhaus ADME, Treanor JJ, Hayden FG, Osterhaus AD, Treanor JJ, et al. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenza virus infections. *N Engl J Med* 1997;337:874-880.
27. Hayden FG, Treanor JJ, Fritz RS, Lobo M, Betts RF, Miller M, et al. Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza: randomized controlled trials for prevention and treatment. *JAMA* 1999;282:1240-1246.
28. Monto AS, Robinson DP, Herlocher ML, Hinson JM Jr, Elliott MJ, Crisp A. Zanamivir in the prevention of influenza among healthy adults: a randomized controlled trial. *JAMA* 1999;282:31-35.
29. Hayden FG, Atmar RL, Schilling M, Johnson C, Poretz D, Paar D, et al. Use of the selective oral neuraminidase inhibitor oseltamivir to prevent influenza. *N Engl J Med* 1999;341:1336-1343.
30. Eisenfeld L, Perl L, Burke G, Blackington S, York E, Regan H, et al. Lack of compliance with influenza immunization for caretakers of neonatal intensive care unit patients. *Am J Infect Control* 1994;22:307-311.
31. Centers for Disease Control and Prevention. Update: influenza activity—United States: 1997-98 season. *MMWR* 1998;47:196-200.
32. Centers for Disease Control and Prevention. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). *MMWR* 1998;47:1-26.
33. Weingarten S, Staniloff H, Ault M, Miles P, Bamberger M, Meyer RD. Influenza surveillance in an acute care hospital. *Arch Intern Med* 1988;148:113-116.

Early-Onset Versus Late-Onset Nosocomial Pneumonia in ICU

Gina Pugliese, RN, MS
Martin S. Favero, PhD

Ibrahim and colleagues, from the Washington University School of Medicine, report on a study designed to compare the clinical outcomes of critically ill patients developing early-onset nosocomial pneumonia ([NP] ie, within 96 hours of ICU admission) and late-onset NP (ie, occurring after 96 hours of ICU admission). It was a prospective cohort study in a medical ICU and a surgical ICU from a university-affiliated urban teaching hospital. Between July 1997 and November 1998, 3,668 patients were prospectively evaluated.

The results showed that 420 patients (11.5%) developed NP. Early-onset NP was observed in 235 patients (56.0%), whereas 185 patients (44.0%) developed late-onset NP. Among patients with early-onset NP, 114 patients (48.5%) spent at least 24 hours in the hospital prior to ICU admis-

sion, compared to 57 patients (30.8%) with late-onset NP ($P=.001$). One hundred eighty-three patients (77.9%) with early-onset NP received antibiotics prior to the development of NP, as compared to 162 patients (87.6%) with late-onset NP ($P=.010$). The most common pathogens associated with early-onset NP were *Pseudomonas aeruginosa* (25.1%), oxacillin-sensitive *Staphylococcus aureus* (OSSA; 17.9%), oxacillin-resistant *S aureus* (ORSA; 17.9%), and *Enterobacter* species (10.2%). *P aeruginosa* (38.4%), ORSA (21.1%), *Stenotrophomonas maltophilia* (11.4%), OSSA (10.8%), and *Enterobacter* species (10.3%) were the most common pathogens associated with late-onset NP. The ICU length of stay was significantly longer for patients with early-onset NP (10.3 ± 8.3 days; $P<.001$) and late-onset NP (21.0 ± 13.7 days; $P<.001$), as compared to patients without NP (3.5 ± 3.2 days). Hospital mortality was significantly greater for patients with early-onset NP (37.9%; $P=.001$) and late-onset NP

(41.1%; $P=0.001$) compared to patients without NP (13.1%).

The authors concluded that both early-onset and late-onset NP are associated with increased hospital mortality rates and prolonged lengths of stay. The pathogens associated with NP were similar for both groups. This may be due, in part, to the prior hospitalization and use of antibiotics in many patients developing early-onset NP. These data suggest that *P aeruginosa* and ORSA can be important pathogens associated with early-onset NP in the ICU setting. Additionally, clinicians should be aware of the common microorganisms associated with both early-onset NP and late-onset NP in their hospitals in order to avoid the administration of inadequate antimicrobial treatment.

FROM: Ibrahim EH, Ward S, Sherman G, Kollef MH. A comparative analysis of patients with early-onset and late-onset nosocomial pneumonia in the ICU setting. *Chest* 2000;117:1434-1442.